US 10889817
Oligonucleotide therapy for Leber Congenital Amaurosis
granted A61KA61K31/7125A61P
Quick answer
US patent 10889817 (Oligonucleotide therapy for Leber Congenital Amaurosis) held by ProQR Therapeutics II B.V. expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ProQR Therapeutics II B.V.
- Grant date
- Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K31/7125, A61P, A61P27/02